| Expression pattern: |
UP |
| Associated gene: |
PFKP, Ago2 |
| Associated microRNA: |
miR-497-5p |
| Biological function: |
circLDLRAD3 promotes lung cancer cell viability, proliferation, migration, invasion, glycolysis metabolism and tumor growth, and inhibits apoptosis. |
| Molecular mechanism: |
circLDLRAD3 functions as a miR-497-5p sponge to increase PFKP expression, thereby promoting lung cancer progression and glycolysis. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); glycolysis (promotes); ceRNA regulation (other); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Transwell Assay; Wound Healing Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
Higher circLDLRAD3 expression was tightly correlated with tumor size, advanced TNM stages and lymph node metastasis; targeting circLDLRAD3 might be a potential targeted therapy for lung cancer treatment. |
| Description: |
circLDLRAD3 is up-regulated in lung cancer tissues and cells and is associated with more aggressive clinicopathologic features. Functionally, circLDLRAD3 promotes lung cancer cell proliferation, migration, invasion, glycolysis and xenograft tumor growth while suppressing apoptosis. Mechanistically, it acts as a miR-497-5p sponge to increase PFKP expression, suggesting the circLDLRAD3/miR-497-5p/PFKP axis as a potential therapeutic target. |
| Confidence score: |
0.8299 |